혈우병 = Hemophilia

다국어 초록 (Multilingual Abstract)

Hemophilia is the most common coagulation disorder. It has a long history. Hemophilia A is caused by FVIII gene mutation, and hemophilia B by FIX gene mutation. Those genes are located on X chromosome long arm. Bleedings in hemophiliacs predominantly occur in joints and muscles. Because those site are insufficient in tissue factor to induce hemostasis. Among joints knee, ankle and elbow are most frequently affected because their synovial structure is vulnerable to injury compared to other joints. Hemophilia is diagnosed with factor assay. Severe hemophilia is below 1% of FVIII:C, moderate between 1% and 5%, mild over 5%. Carrier detection and prenatal diagnosis have been conducted with RFLP-based linkage analysis and DNA sequencing. Mainstay of treatment is factor replacement therapy so far. Bleedings can be controlled by infusion of factor concentrates. Hemophilc arthropathy and muscle contracture are representative sequelae. Complications of facotor replacement therapy are inhibitor development and infections. Hemophiliacs with inhibitor should be managed with large dose factor concentrate, bypassing agent, ITI and immunosuppression. Ultimately, hemophilia could be cured by gene therapy.

참고문헌 (Reference)

1 "Tissue factor an factor VII initiation of coagulation" Linppincott Williams & Wilkins 89-101, 2001

2 "The molecular analysis of haemophilia A:a guideline from the UK haemophilia centre doctor's organization haemophilia genetics laboratory network" 11 : 387-397, 2005

3 "The diagnosis of hemophilia A and B and von Willebrand's disease" Chapman & Hall Medical 54-62, 1997

4 "Structure, biology, and genetics of factor VIII" Elsevier churchill livingstone 2011-2030, 2005

5 "Safer clotting factor concentrates" Chapman & Hall Medical 307-332, 1997

6 "Safer clotting factor concentrates" Chapman & Hall Medical 307-332, 1997

7 "Musculoskeletal bleeding in hemophilia" Chapman & Hall Medical 115-122, 1997

8 "Immunoradiometric measurement of factor VIII procoagulant antigen" 62 : 1048-52, 1978

9 "Immunology of inhibitor development in hemophilia A" 29 : 69-75, 2003

10 "High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate" 203 : 312-, 1964

11 "High prevalence of elevated facotor VIII levels in patients referred for thrombophilia screening:role of increased synthesis and relationship to the acute phase reaction" 77 : 825-828, 1997

12 "Heredity in hemophilia" Octapharma 19-24, 2004

13 "Hemophilia in the Talmud and rabbinic writings" 70 : 833-7, 1969

14 "Factor VIII concentrate" Chapman & Hall Medical 181-192, 1997

15 "Diagnosis of hemophilia A and B carriers and prenatal diagnosis" Chapman & Hall Medical 63-74, 1997

16 "Collection, transport, and processing of blood specimens for coagulation testing and general performance of coagulation assays; approved guideline-third edition" NCCLS 4-5, 1998

17 "Clinical practice of hemostasis and thrombosis" Koonja 67-87, 1997

18 "Clinical aspects and therapy of hemophilia" Elsevier churchill livingstone 2047-2065, 2005

19 "Blood-induced joint damage : an overview of musculoskeletal research in haemophilia." Blackwell Science 18-26, 2000

20 "Blood history" Erum Publishing 67-101, 1998

21 "Annual report 2005" KHF 23-37, 2005

22 "Annual report 2005" KHF 23-37, 2005